METADATA last updated: 2026-01-21 RT file_name: LAMP Primers UPDATED 12-17-2020.xlsx file_date: 2020-12-17 title: LAMP Primers UPDATED 12-17-2020 category: guides subcategory: operations tags: source_file_type: xlsx xfile_type: xlsx gfile_url: https://docs.google.com/spreadsheets/d/1yrgBbJJtmFw3edxbjYx7XaO3ecsXNemaOtbrY2RnuoY xfile_github_download_url: https://raw.githubusercontent.com/FocusOnFoundationsNonprofit/floodlamp-archive/main/guides/operations/LAMP%20Primers%20UPDATED%2012-17-2020.xlsx.xlsx pdf_gdrive_url: NA pdf_github_url: NA conversion_input_file_type: xlsx conversion: pandas license: CC BY 4.0 - https://creativecommons.org/licenses/by/4.0/ tokens: 1630 words: 520 notes: summary_short: The FloodLAMP LAMP Primers list (updated 12/17/2020) specifies SARS-CoV-2 and human internal control primer sets derived from the Rabe–Cepko protocol, including sequences, mix concentrations, and ordering/handling notes (HPLC purification, resuspension, packaging, and minimum order quantities). It provides premix targets for 30X stock solutions for ORF1ab (AS1e), E gene (E1), N gene (N2), and human controls (RNaseP and ACTB) to support standardized assay preparation and procurement. CONTENT ***INTERNAL TITLE:*** LAMP Primers UPDATED 12-17-2020 - FloodLAMP Contact Randy True randy@floodlamp.bio - from Rabe Cepko | [Proc Natl Acad Sci 2020 Sep 29;117(39):24450-24458. doi: 10.1073/pnas.2011221117. Epub 2020 Sep 8.](https://pubmed.ncbi.nlm.nih.gov/32900935/) - Harvard University IP - All oligos 5' to 3' - 6 Primer per set to be premixed at 30X concentration - All primers HPLC purified - Resuspended in DNAse RNAse free water, shipped on cold packs - Supplied in 1ml tubes - MOQ 25 x 1ml tubes (10K rxns at 2.5ul per reaction of 10X) | **As1e - ORF1ab (SARS-CoV-2)** | | | 30X μM | ml | total nmoles | |------------------------------|-----------------------------------------------------|--------------|----------|------|----------------| | As1e_FIP | TCAGCACACAAAGCCAAAAATTTATTTTTCTGTGCAAAGGAAATTAAGGAG | 51.0 | 48.0 | 25.0 | 1200.0 | | As1e_BIP | TATTGGTGGAGCTAAACTTAAAGCCTTTTCTGTACAATCCCTTTGAGTG | 49.0 | 48.0 | | 1200.0 | | As1_F3 | CGGTGGACAAATTGTCAC | 18.0 | 6.0 | | 150.0 | | As1_B3 | CTTCTCTGGATTTAACACACTT | 22.0 | 6.0 | | 150.0 | | As1_LF | TTACAAGCTTAAAGAATGTCTGAACACT | 28.0 | 12.0 | | 300.0 | | As1_LB | TTGAATTTAGGTGAAACATTTGTCACG | 27.0 | 12.0 | | 300.0 | | | | | | | | | | | | | | | | **E1 - E Gene (SARS-CoV-2)** | | | | | | | E1-FIP | ACCACGAAAGCAAGAAAAAGAAGTTCGTTTCGGAAGAGACAG | 42.0 | 48.0 | | | | E1-BIP | TTGCTAGTTACACTAGCCATCCTTAGGTTTTACAAGACTCACGT | 44.0 | 48.0 | | | | E1-F3 | TGAGTACGAACTTATGTACTCAT | 23.0 | 6.0 | | | | E1-B3 | TTCAGATTTTTAACACGAGAGT | 22.0 | 6.0 | | | | E1-LF | CGCTATTAACTATTAACG | 18.0 | 12.0 | | | | E1-LB | GCGCTTCGATTGTGTGCGT | 19.0 | 12.0 | | | | | | | | | | | **N2 - N Gene (SARS-CoV-2)** | | | | | | | N2-FIP | TTCCGAAGAACGCTGAAGCGGAACTGATTACAAACATTGGCC | 42.0 | 48.0 | | | | N2-BIP | CGCATTGGCATGGAAGTCACAATTTGATGGCACCTGTGTA | 40.0 | 48.0 | | | | N2-F3 | ACCAGGAACTAATCAGACAAG | 21.0 | 6.0 | | | | N2-B3 | GACTTGATCTTTGAAATTTGGATCT | 25.0 | 6.0 | | | | N2-LF | GGGGGCAAATTGTGCAATTTG | 21.0 | 12.0 | | | | N2-LB | CTTCGGGAACGTGGTTGACC | 20.0 | 12.0 | | | | | | | | | | | **RNAseP (Human IC)** | | | | | | | RNP-FIP | GTGTGACCCTGAAGACTCGGTTTTAGCCACTGACTCGGATC | 41.0 | 48.0 | | | | RNP-BIP | CCTCCGTGATATGGCTCTTCGTTTTTTTCTTACATGGCTCTGGTC | 45.0 | 48.0 | | | | RNP-F3 | TTGATGAGCTGGAGCCA | 17.0 | 6.0 | | | | RNP-B3 | CACCCTCAATGCAGAGTC | 18.0 | 6.0 | | | | RNP-LF | ATGTGGATGGCTGAGTTGTT | 20.0 | 12.0 | | | | RNP-LB | CATGCTGAGTACTGGACCTC | 20.0 | 12.0 | | | | | | | | | | | **ActinB (Human IC)** | | | | | | | ACTB-FIP | GAGCCACACGCAGCTCATTGTATCACCAACTGGGACGACA | 40.0 | 48.0 | | | | ACTB-BIP | CTGAACCCCAAGGCCAACCGGCTGGGGTGTTGAAGGTC | 38.0 | 48.0 | | | | ACTB-F3 | AGTACCCCATCGAGCACG | 18.0 | 6.0 | | | | ACTB-B3 | AGCCTGGATAGCAACGTACA | 20.0 | 6.0 | | | | ACTB-LF | TGTGGTGCCAGATTTTCTCCA | 21.0 | 12.0 | | | | ACTB-B | CGAGAAGATGACCCAGATCATGT | 23.0 | 12.0 | | | ||